ELAC2 and prostate cancer: We analysed the nuclear and mitochondrial transcriptomes and proteomes, miRNAs and small RNAs to show that reduced ELAC2 levels and activity predispose to prostate cancer by impairing the function of noncoding RNAs such as tRNAs, lncRNAs and miRNAs, which in turn alter immunometabolism.